Clovis Oncology up after prostate cancer drug meets main goal in late-stage study

Clovis Oncology

03/10/2022 13:34

** Clovis Oncology Inc's shares  CLVS.O  rise 14.2% to $1.36
premarket
    ** Co says its experimental drug to treat a type of prostate
cancer with a genetic mutation has achieved main goal in
late-stage study  urn:newsml:reuters.com:*:nBwb9YKHqa
    ** The drug, Rubraca, when compared to control group, which
were administered range of physician recommended treatment,
significantly improved length of time during which patients
disease did not get worse
    ** Co plans to file the data from the study to U.S. health
regulators in Q1 2023
    ** Rubraca has already been approved by U.S. FDA to treat
ovarian cancer 
    ** Up to Friday's close, stock had fallen ~56% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))